





John M. Capek | Abbott Newsroom

















 

















PRESS RELEASES
PRESS CONTACTS
MEDIA LIBRARY
HONORS
EXPERTS

EXECUTIVE TEAM






JOHN M. CAPEK, Ph.D.




Executive Vice President, Ventures
John Capek, Ph.D., is Executive Vice President, Ventures. Dr. Capek was appointed to his current position in June 2015. In this role, he leads Abbott’s venture investment organization as well as new ventures, including Abbott Electrophysiology. Previously, he had served as Executive Vice President, Medical Devices, and Senior Vice President, Abbott Vascular, heading up Abbott's global vascular business.
Before joining Abbott, Dr. Capek served in various management roles at Guidant Corporation, including president, Guidant Vascular Intervention and vice president and general manager of Bioabsorbable Vascular Solutions. He also served as vice president and general manager of Guidant Germany and vice president, marketing, Guidant Cardiac Rhythm Management Group. Before joining Guidant, Dr. Capek was manager of New Product Technology at Eli Lilly & Company.
He has a bachelor's degree in biomedical engineering, a master's degree in biomedical engineering, a master's degree in electrical engineering, a Ph.D. in biomedical engineering and a master's degree in business administration from Rensselaer Polytechnic Institute.











Careers


Investors


Newsroom


Citizenship


Partners


Contact


SITE MAP


POLICIES


privacy policy


Terms & Conditions



true


accessibility


You are about to exit for another Abbott country or region specific website
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.
Do you wish to continue and exit this website?



yesno



accessibility


You are about to exit the Abbott family of websites for a 3rd party website
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.
Do you wish to continue and exit this website?



yesno



accessibility

Asset Warning


yesno






























ABT John M. Capek Insider Trades for Abbott Laboratories


































Bulletin






Investor Alert







New York Markets Close in:



Market Snapshot
Winners and Losers


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Abbott Laboratories

                  NYSE: ABT
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Abbott Laboratories



Countdown to close
 --Real time quotes
Jul 24, 2017, 3:22 p.m.


ABT

/quotes/zigman/216393/composite


$
50.91




Change

+0.07
+0.13%

Volume
Volume 5.34m
Real time quotes








/quotes/zigman/216393/composite
Previous close

$
			50.84
		


$
				50.91
			
Change

+0.07
+0.13%





Day low
Day high
$50.47
$50.99










52 week low
52 week high

            $37.38
        

            $51.13
        


















Insider Activity


Individual




John M. Capek



Dr. John M. Capek is Executive Vice President-Ventures at Abbott Laboratories and President at Abbott Cardiovascular Systems, Inc.
Dr. Capek was previously employed as Senior Vice President by Abbott Vascular, Inc., President by Guidant Vascular Intervention, Vice President & General Manager by Bioabsorbable Vascular Solutions, a Manager-New Product Technology by Eli Lilly & Co., Vice President & General Manager by Guidant GmbH, and Vice President-Marketing by Guidant Cardiac Rhythm Management Group.
He received his undergraduate degree from Rensselaer Polytechnic Institute, a graduate degree from Rensselaer Polytechnic Institute, an MBA from Rensselaer Polytechnic Institute, and a doctorate degree from Rensselaer Polytechnic Institute.



Transactions


Date
Shares
Transaction
Value





02/28/2017
10,815


 
Derivative/Non-derivative trans. at $45.46 per share.


491,650


02/21/2017
93,400


 
Disposition at $45 per share.


4,203,000


02/21/2017
93,400


 
Derivative/Non-derivative trans. at $26.7 per share.


2,493,780


02/17/2017
14,273


 
Award at $0 per share.


0


11/16/2016
22,000


 
Derivative/Non-derivative trans. at $24.38 per share.


536,360


02/29/2016
9,980


 
Derivative/Non-derivative trans. at $39.52 per share.


394,410


02/19/2016
24,414


 
Award at $0 per share.


0


02/27/2015
12,312


 
Derivative/Non-derivative trans. at $47.61 per share.


586,175


02/20/2015
23,457


 
Award at $0 per share.


0


02/04/2015
400


 
Disposition at $45.86 per share.


18,344


02/04/2015
300


 
Disposition at $45.75 per share.


13,725


02/04/2015
1,300


 
Disposition at $45.61 per share.


59,293


02/04/2015
2,200


 
Disposition at $45.85 per share.


100,870


02/04/2015
2,900


 
Disposition at $45.74 per share.


132,646


02/04/2015
400


 
Disposition at $45.61 per share.


18,244


02/04/2015
300


 
Disposition at $45.85 per share.


13,755


02/04/2015
700


 
Disposition at $45.74 per share.


32,018


02/04/2015
2,300


 
Disposition at $45.6 per share.


104,880


02/04/2015
100


 
Disposition at $45.84 per share.


4,584


02/04/2015
5,000


 
Disposition at $45.73 per share.


228,650


02/04/2015
200


 
Disposition at $45.6 per share.


9,120


02/04/2015
200


 
Disposition at $45.84 per share.


9,168


02/04/2015
100


 
Disposition at $45.73 per share.


4,573


02/04/2015
1,600


 
Disposition at $45.59 per share.


72,944


02/04/2015
1,935


 
Disposition at $45.83 per share.


88,682


02/04/2015
1,300


 
Disposition at $45.73 per share.


59,449


02/04/2015
1,400


 
Disposition at $45.58 per share.


63,812


02/04/2015
100


 
Disposition at $45.82 per share.


4,582


02/04/2015
2,500


 
Disposition at $45.71 per share.


114,275


02/04/2015
100


 
Disposition at $45.83 per share.


4,583


02/04/2015
2,300


 
Disposition at $45.72 per share.


105,156


02/04/2015
100


 
Disposition at $45.58 per share.


4,558


02/04/2015
500


 
Disposition at $45.82 per share.


22,910


02/04/2015
600


 
Disposition at $45.71 per share.


27,426


02/04/2015
4,300


 
Disposition at $45.81 per share.


196,983


02/04/2015
2,500


 
Disposition at $45.7 per share.


114,250


02/04/2015
400


 
Disposition at $45.81 per share.


18,324


02/04/2015
100


 
Disposition at $45.7 per share.


4,570


02/04/2015
900


 
Disposition at $45.81 per share.


41,229


02/04/2015
2,600


 
Disposition at $45.69 per share.


118,794


02/04/2015
1,373


 
Disposition at $45.8 per share.


62,884


02/04/2015
100


 
Disposition at $45.69 per share.


4,569


02/04/2015
100


 
Disposition at $45.8 per share.


4,580


02/04/2015
600


 
Disposition at $45.69 per share.


27,414


02/04/2015
1,800


 
Disposition at $45.8 per share.


82,440


02/04/2015
2,700


 
Disposition at $45.68 per share.


123,336


02/04/2015
400


 
Disposition at $45.79 per share.


18,316


02/04/2015
100


 
Disposition at $45.68 per share.


4,568


02/04/2015
200


 
Disposition at $45.79 per share.


9,158


02/04/2015
900


 
Disposition at $45.68 per share.


41,112


02/04/2015
1,100


 
Disposition at $45.79 per share.


50,369


02/04/2015
2,500


 
Disposition at $45.67 per share.


114,175


02/04/2015
800


 
Disposition at $45.83 per share.


36,664


02/04/2015
100


 
Disposition at $45.72 per share.


4,572


02/04/2015
100


 
Disposition at $45.57 per share.


4,557


02/04/2015
1,600


 
Disposition at $45.78 per share.


73,248


02/04/2015
700


 
Disposition at $45.67 per share.


31,969


02/04/2015
100


 
Disposition at $45.78 per share.


4,578


02/04/2015
3,987


 
Disposition at $45.66 per share.


182,047


02/04/2015
2,400


 
Disposition at $45.78 per share.


109,872


02/04/2015
100


 
Disposition at $45.66 per share.


4,566


02/04/2015
4,000


 
Disposition at $45.77 per share.


183,080


02/04/2015
500


 
Disposition at $45.66 per share.


22,830


02/04/2015
100


 
Disposition at $45.77 per share.


4,577


02/04/2015
2,700


 
Disposition at $45.65 per share.


123,255


02/04/2015
3,016


 
Disposition at $45.77 per share.


138,043


02/04/2015
200


 
Disposition at $45.65 per share.


9,130


02/04/2015
1,384


 
Disposition at $45.76 per share.


63,332


02/04/2015
1,700


 
Disposition at $45.64 per share.


77,588


02/04/2015
200


 
Disposition at $45.76 per share.


9,152


02/04/2015
700


 
Disposition at $45.63 per share.


31,941


02/04/2015
400


 
Disposition at $45.76 per share.


18,304


02/04/2015
300


 
Disposition at $45.63 per share.


13,689


02/04/2015
900


 
Disposition at $45.75 per share.


41,175


02/04/2015
805


 
Disposition at $45.62 per share.


36,725


02/04/2015
3,900


 
Disposition at $45.82 per share.


178,698


02/04/2015
800


 
Disposition at $45.72 per share.


36,576


02/04/2015
83,000


 
Derivative/Non-derivative trans. at $25.25 per share.


2,095,750


02/28/2014
13,263


 
Derivative/Non-derivative trans. at $39.79 per share.


527,735


02/21/2014
23,109


 
Award at $0 per share.


0


02/28/2013
15,105


 
Derivative/Non-derivative trans. at $34.26 per share.


517,498


02/19/2013
12,147


 
Derivative/Non-derivative trans. at $35.08 per share.


426,117


02/15/2013
28,800


 
Award at $0 per share.


0





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. Miles D. White 
Chairman & Chief Executive Officer




Mr. Brian B. Yoor 
Chief Financial Officer & Executive VP-Finance




Dr. Eric S. Fain 
Senior Vice President




Mr. Denis M. Gestin 
Senior VP-Global Commercial Integration




Mr. Randel W. Woodgrift 
Vice President-Global Operations




Mr. James E. Young 
Chief Compliance & Ethics Officer, Vice President




Mr. Jean-Yves F.  Pavée 
Senior Vice President-Established Pharmaceuticals




Dr. John M. Capek 
Executive Vice President-Ventures




Mr. Richard W. Ashley 
Executive Vice President-Corporate Development




Mr. Corlis D. Murray 
Senior VP-Quality Assurance & Regulatory




Mr. Brian J. Blaser 
Executive Vice President-Diagnostics Products




Dr. Gene  Huang 
Chief Economist & Vice President




Mr. John G. Stratton 
Director




Mr. Daniel J. Starks 
Director




Ms. Karen M. Peterson 
Treasurer & Vice President




Ms. Elaine R. Leavenworth 
Chief Marketing Officer & Senior Vice President




Mr. Robert E. Funck 
Vice President-Controller




Mr. Aj J. Shoultz 
Vice President-Taxes




Mr. David P. Mark 
Vice President-Internal Audit




Mr. Scott  Stoffel 
Media Relations Contact




Mr. P. Claude Burcky 
Vice President-International Government Affairs




Mr. Scott  Leinenweber 
Vice President-Investor Relations




Mr. Stephen R. Fussell 
Executive Vice President-Human Resources




Mr. Hubert L. Allen 
Secretary, Executive VP & General Counsel




Ms. Kathryn S. Collins 
Vice President-Commercial Legal Operations




Mr. Samuel C. Scott 
Independent Director




Mr. Glenn Fletcher Tilton 
Independent Director




Mr. Edward Michael Liddy 
Independent Director




Ms. Phebe N. Novakovic 
Independent Director




Dr. Robert J. Alpern 
Independent Director




Mr. William A. Osborn 
Lead Independent Director




Mr. Jim  Farrell 
Independent Director




Ms. Roxanne Schuh Austin 
Independent Director




Dr. Sally E. Blount 
Independent Director




Ms. Nancy  McKinstry 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




3:22 PM EDT
July 24, 2017


/marketstate/country/us
New York

	Open


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
3:18pTrump administration stymies push for improved climate-risk disclosure among companies
3:17pAlphabet earnings: A $2.74 billion hit for Google, potential YouTube results for investors
3:17pBoeing earnings: Management will likely make a big deal about its services business
3:07pNo retreat: Fed to stick to plans for rate hike, balance-sheet selloff this year
3:06pConstellation Brands, Boston Beer shares slide after Goldman Sachs downgrades
3:06pAMD puts Intel in the crosshairs with fast-and-cheap Threadripper chip
3:03pWhy you should be worried about this part of the New York real-estate market
3:03pBarron's Bounce: Meaty Gains for Leucadia
3:01pGold settles lower, ending 6-session streak of gains
3:01pHow housekeepers, takeout food and grocery delivery are making us happier
2:58pDow, S&P 500 edge lower while Nasdaq sets intraday record 
2:56pBoston Beer downgraded to sell at Goldman Sachs
2:56pCPRRECTED" Constellation Brands downgraded to neutral at Goldman Sachs
2:55pCORRECTED: Goldman Sachs sets Constellation Brands price target at $210
2:50p‘Game of Thrones’ science: Let’s take a closer look at that greyscale
2:49pOil prices finish higher after news of Saudi pledge to cut exports, Nigeria plans to cap output
2:49pConstellation Brands shares down 1.2% 
2:47pMove over, Airbnb: Here’s how to rent out your home for a lot more money
2:47p‘Robot parents’ can even read your child bedtime stories
2:46pCompanies do better when CEO pay dwarfs average worker, study finds
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,541.77

-38.30
-0.18%





nasdaq

/quotes/zigman/12633936/realtime
6,411.93

+24.17
+0.38%





s&p 500

/quotes/zigman/3870025/realtime
2,472.11

-0.43
-0.02%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15






















































 












John M. Capek, Abbott Laboratories EVP, Ventures - REDBOOKS








































Brands, Marketers, Agencies. Search Less. Sell More.





/   SIGN IN

GET A FREE TRIAL   
CONTACT US: (800) 908-5395





















John M. Capek
EVP, Ventures, Abbott Laboratories

EMAIL: 
                      







              Real-time sales trigger feed - generated by REDBOOKS machine learning and natural language processing technology, tracking 800,000+ news sources to aggregate all new executives, job/role changes and news on decision makers, brands and agencies in the media/marketing industry.
              

              This sales feed is for John M. Capek at Abbott Laboratories. John M. Capek works as EVP, Ventures .  Abbott Laboratories is a leader in Pharmaceuticals & Health Care Products .
              REDBOOKS tracks personnel changes for advertisers spending over $1 million annually.
              

              For more  leads or media/marketing prospecting automation, start a free trial now.
              

Recent Related News

01/28/2016:


Health Tech Incubator MATTER, Abbott Partner to Support Healthcare Innovation

..... MATTER’s strategic partnerships, such as the one with Abbott, enable established companies and startup entrepreneurs to work together, helping to develop solutions to the most meaningful healthcare problems in the right ways, at the right times.
“At Abbott, we are on a mission to help people live their best lives, and innovation is at the center of everything we do,” said John Capek, executive vice president, Ventures, Abbott. “We look forward to collaborating with entrepreneurs and other industry leaders at MATTER to identify and support the growth of next-generation technologies that help people live better, more fulfilling lives......

People In This Article:
John M. Capek
 

09/03/2015:


Abbott Completes Acquisition of Tendyne Holdings

Sept. 2 -- Abbott (NYSE: ABT) announced today that it has completed its acquisition of Tendyne Holdings, Inc., a private medical device company focused on developing minimally invasive mitral valve replacement therapies. Abbott acquired the equity of Tendyne that it did not already own for $225 million upfront, resulting in a total transaction value of $250 million, plus potential future payments tied to regulatory milestones......

People In This Article:
John M. Capek
 






Learn more about John M. Capek  and 260,000+ key contacts

  Create targeted lead lists

  Gain insider knowledge with advanced machine  learning
  Real-time verified contact info



Enter Work Email:

Please enter email address.
 Please enter valid email address.









             Learn more about John M. Capek and 260,000+ key contacts
            



























First Name *

 Please enter first name.




Last Name *

 Please enter last name.






Company Name *

 Please enter company name.






Email *





Phone *

 Please enter phone number.
 Please enter 10 digits number.





What industry are you in? *  
                (Please select one the categories below)
Please enter value for the industry.




                     Media Sales
                  




                     Production
                  




                     Ad-Tech/Mar-Tech
                  




                     Sponsorship Sales
                  



  Agency New Business
                  



  Other:
                  




What is your role? *
                 
                 (Please select one the categories below)
Please enter value for the role.



  C-Suite
                  



  VP/Manager
                  



  Sales Rep
                  



  Other:
                  














Thank you for registering for a Free REDBOOKS.com Trial!
We are processing your request and will be in touch shortly to get you started!
For Immediate Assistance, please call us at (800) 908-5395 or email us at info@redbooks.com


























Home
Learn More
FREE Trial


Features




AD THINK Events
Thought Leadership Events
Top Advertiser Directory
Top Agency Directory



Add Your Agency
Update Your Agency
Agency Showcase
Advertising Associations
Creative Spotlight
Services and Suppliers


About Us
Blog
Contact Us
Jobs
Terms & Conditions
Privacy Policy





Customer Support
(800) 908-5395
Connect with us




















Copyright © 2017 Red Books LLC. All rights reserved


































John M. Capek - Executive Vice President, Ventures at Abbott Laboratories



























































                      NEWS HOME
                    

Advertising
Board and Executive Moves
Energy
Health Care
Hedge Funds
M & A
Private Equity
Technology








            You have  
            
9 free profiles

              left this month   
			      

                Start Your Free Trial ➤
              








            Hey, we noticed you're a RelSci Pro subscriber! Would you like to view the page there?
            

                View on RelSci Pro ➤
              




























































































































Email







LinkedIn







Facebook







Google+







Tweet







Reddit





Permalink





John M. Capek
Executive Vice President, Ventures at Abbott Laboratories



Overview
In The News Relationships Paths
Education Career History Political Donations Public Holdings Transactions 


John M. Capek
Executive Vice President, Ventures at Abbott Laboratories



 Overview



Age



55
                                  (Born 1962)
                                              




Notable Companies


Abbott Vascular, Inc.

Guidant Vascular Intervention




Number of Relationships



                This person is connected to 416 people.
              






 In The News
          See more




PR Newswire
September 2, 2015





                        Abbott Completes Acquisition of Tendyne Holdings, Inc.                    





PR Newswire
July 30, 2015





                        Abbott to Broaden Foundation in Structural Heart Therapies with Two Mitral Valve Transactions- Acquisition of Tendyne Holdings, Inc. to Expand Abbott's Mitral Valve Therapies                    





Chicago Tribune
October 29, 2014





                        Abbott acquires heart rhythm technology company                    







See full news coverage and complete stories with RelSci Professional.

Create Your News Feed








See  More 






 Relationships
              See Details




Miles D. White

Chief Executive Officer at Abbott Laboratories




Hubert L. Allen

Executive Vice President, General Counsel & Secretary at Abbott Laboratories





Brian B. Yoor

Chief Financial Officer & Executive Vice President-Finance at Abbott Laboratories




Robert E. Funck

Vice President, Chief Ethics & Compliance Officer at Abbott Laboratories





Charles D. Foltz

Senior Vice President at Abbott Vascular, Inc.




Elaine R. Leavenworth

Chief Marketing Officer & Senior Vice President at Abbott Laboratories





Brian Wentworth

Head of Investments, Abbott Laboratories Pension Plan at Abbott Laboratories




Gerald Schochetman

Director, AIDS Research & Retrovirus Discovery at Abbott Laboratories





Rich Kaufman

Chief Operating Officer at Intersect ENT, Inc.




Katharine Wyatt

Director of Trust Investments, Abbott Laboratories Pension Plan at Abbott Laboratories







See 406 more listings with RelSci Professional.

Start My Free Trial ➤








See 406 More 


 


 Paths to John M. Capek



            John M. Capek          




 You



 Connections via Relationship Science



 John M. Capek






Sync your contacts to see how you can connect with John M. Capek.

Start My Free Trial ➤








See  More 


 


 Educational Background



MBA in Management 
Class of 1987 


Rensselaer Polytechnic Institute - Lally School of Management & Technology

                  Lally School of Management & Technology is a school in Troy.                




ME in Electrical Engineering 


Rensselaer Polytechnic Institute

                  Rensselaer Polytechnic Institute, or RPI, is a private research university located in Troy, New York, with two additional campuses in Hartford and Groton, Connecticut. It was founded in 1824 by Stephen van Rensselaer and Amos Eaton for the "application of science to the common purposes of life" and is the oldest technological university in the English-speaking world.                





 Career History



Executive Vice President, Ventures

                                    2006 - Current                


Abbott Laboratories


                  Abbott Laboratories engages in the discovery, development, manufacture and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Vascular Products. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure and other medical device products. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.                




Vice President

                                    2006 - ?                


Abbott Vascular, Inc.


                  Abbott Vascular, Inc., part of Abbott Laboratories, is a company headquartered in Abbott Park, IL, focused on surgical and medical instruments and apparatus.                




Elected Corporate Officer

                                    2003 - ?                


Bioabsorbable Vascular Solutions, Inc.


                  BioStent, Inc. Develops fully bioabsorbable vascular stent platforms. The company is headquartered in Santa Clara, CA.                




President

                                    2003 - 2006                


Guidant Vascular Intervention






Vice President & General Manager

                                    Prior                


Guidant GmbH






Vice President-Marketing

                                    Prior                


Guidant Cardiac Rhythm Management Group






Manager-New Product Technology

                                    Prior                


Eli Lilly & Company


                  Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. It operates through the Human Pharmaceutical Products and Animal Health segments. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing, and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular, and other. The Animal health segment operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. The Animal health products include Rumensin, Tylan, Posilac, Paylean and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The Other Pharmaceuticals products include anti-infectives, primarily Vancocin and Ceclor, and other miscellaneous pharmaceutical products and services. Its products are distributed through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.                





 Political Donations



$251

                  2014                


Abbott Laboratories Better Government Fund







$251

                  2013                


Abbott Laboratories Better Government Fund







$488

                  2012                


Abbott Laboratories Better Government Fund







$488

                  2011                


Abbott Laboratories Better Government Fund







$732

                  2010                


Abbott Laboratories Better Government Fund









See 3 more listings with RelSci Professional.

Start My Free Trial ➤








See 3 More 






 Public Holdings






Restricted data only for RelSci Professional users.

Start My Free Trial ➤








See  More 


 


 Transactions



 Details Hidden



                  Abbott Laboratories raised money in a private placement transaction                                  




 Details Hidden



                  Abbott Laboratories raised money in a private placement transaction                                  





 Other Affiliations




              John M. Capek is affiliated with
                            Abbott Laboratories, Abbott Vascular, Inc., Bioabsorbable Vascular Solutions, Inc., Guidant Vascular Intervention, Guidant GmbH, Guidant Cardiac Rhythm Management Group, Eli Lilly & Company.
            





You've reached your 10 free profiles limit this month.
Upgrade to RelSci Pro today to enjoy unlimited article views and much more!

Start My Free Trial  ➤

Still not convinced? Check out our full listing of features here.












Are you a RelSci Pro Subscriber?

Login to RelSci Pro 
                        ➤


Not a Pro Subscriber? Log in here to manage your alerts









 Keep me signed in.
        

Login  ➤



        Forgot your Password?
    

























 I have read the LexisNexis terms & conditions




Sign Me Up  ➤


















John M Capek - Winnetka, IL | Intelius



























Sign In



We found John M Capek in Winnetka, IL


John M Capek

                                                                           Intelius found that John M Capek  is  a male between 50 and 60 years old from Winnetka, IL.  We have connected them to
                9 addresses,
                8 phones,
                and 3 relatives or associates.
         





Also Known As

John Michael Capek


Get Report Now

Age

John M Capek is in his 50s

John Has Lived In

Winnetka, IL
Los Gatos, CA
Saint Paul, MN

John's Relatives

Allison Capek
Linda Capek
Leah Capek







John M Capek



Zodiac SignScorpio



GenderMale



Professional Status
Senior Vice President at Abbott Laboratories Company



Get Report Now










Want to know more about John? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about John, or use our people search engine to find others.
Get Background Check on John M Capek
Get a Criminal Check on John M Capek
Get a Public Record Report on John M Capek
Get a People Search Report on John M Capek


John M Capek's Contact Information
Known Cities Lived In
Find out where John M Capek has lived as well as John M Capek's phone numbers and email addresses.




John M Capek Has Lived in 4 States
Illinois Address for John M Capek


1234 W******* R* 

Winnetka, IL


Has Lived In

Winnetka, IL
Los Gatos, CA


Get Full Address Report










Phone Numbers Associated with John M Capek

(408) ***-**** - Saratoga, CA 
(847) ***-**** - North Chicago, IL 
(847) ***-**** - North Chicago, IL 


Get Full Phone Report



Email Addresses Associated with John M Capek

j**n@***.com
c***k@***.net
c***k@***.net


Get Email Report




John M Capek's Professional Information
Information regarding John M Capek's professional history.  Find out previous places John M Capek has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


John M Capek Has Worked at 3 Places
Company: Abbott Laboratories Company
               Title: Senior Vice President
Company: Abbott Laboratories Company
               Title: Executive Vice President Ventures
John M Capek's Experience
Title: Senior Vice President
               Company: Abbott Laboratories Company
Job Details
               Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 74,000 people.
Title: Executive Vice President Ventures
               Company: Abbott Laboratories Company
Job Details
               Company Size: $1 bil and above - Employee Range: 25,000 to less than 100,000
Additional Professional Information on John M Capek

 See John M Capek's LinkedIn Profile



John M Capek's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for John M Capek


John M Capek's known Social Networks And Potential Email Matches

Find all of John M Capek's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
John Capek
Username Matches

                  JohnCapek
                  CapekJohn
                  John.Capek
                  Capek.John
                  John_Capek
                  Capek_John
                  John-Capek
                  Capek-John
                  JCapek
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
J Capek







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.











John M. Capek, Exec. VP - Medical Devices, Abbott Vascular Inc.














A publisher of Business Information since 1983   
  





 


   

Search Business Search Executive 
  Advanced Search 




  

Sign In  |  Hints 









Email Profiles And Emails Of Executives 





 

John Capek

 

Exec. VP - Medical Devices

 

John Capek's Email : 
Please login 

 

Company Name : 
Abbott Vascular Inc. 

 

Company Website : 
www.abbottvascular.com 

 

Company Address : 
100 Abbott Pk. Rd., Abbott Park, IL,United States, 


 

John Capek's Profile : 
Exec. VP - Medical Devices 

 

John Capek's Biography : 


John Capek, Ph.D., is executive vice president, medical devices. Capek was appointed to this position in July 2007 and is responsible for Abbott's Vascular, Diabetes Care, Abbott Spine and Animal Health businesses. Previously, he served as senior vice president, Abbott Vascular, heading up Abbott's global vascular business.Capek served in various management roles at Guidant, including president, Guidant Vascular Intervention and vice president and general manager of Bioabsorbable Vascular Solutions. He also served as vice president and general manager of Guidant Germany and vice president, marketing, Guidant Cardiac Rhythm Management Group. He also previously served as vice president, Cardiac Therapies, Abbott Vascular upon the April 2006 acquisition of Guidant. Before joining Guidant, Capek was manager of New Product Technology at Eli Lilly & Company.Capek serves on the board of the American Heart Association.Capek has a bachelor's degree in biomedical engineering, a master's degree in biomedical engineering, a master's degree in electrical engineering, a Ph.D. in biomedical engineering and a master's degree in business administration from Rensselaer Polytechnic Institute. 

 

John Capek's Colleagues :





Name 
Title 
Email 

Miles White 
Chmn., CEO 
Please login 

Roxanne Austin 
Board Dir. 
Please login 

William Daley 
Board Dir. 
Please login 

James Farrell 
Board Dir. 
Please login 

Laurance Fuller 
Board Dir. 
Please login 

* Other executive with same Profile. 











            Home  |  About Us  |  Product Information   |  Subscription  |  List Builder   |  Executive List   |  Email Lists   |  Contact Us  |  Site Map  |  Browse Directory    





 

� 2009, Walkers's Research - A publisher of Business Information since 1983, All Rights Reserved.






ABL John M. Capek Insider Trades for Abbott Laboratories


































Bulletin






Investor Alert







New York Markets Close in:



Market Snapshot
Winners and Losers


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Abbott Laboratories

                  FRA: DE:ABL
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
News
      
Charts
      



Abbott Laboratories




Quotes are delayed by 20 min
Jul 21, 2017, 3:52 p.m.


ABL

/quotes/zigman/216380/delayed


€
43.45




Change

+0.53
+1.23%

Volume
Volume 500
Quotes are delayed by 20 min








/quotes/zigman/216380/delayed
Previous close

€
			42.92
		


€
				43.45
			
Change

+0.53
+1.23%





Day low
Day high
€43.41
€43.72










52 week low
52 week high

            €34.46
        

            €44.20
        


















Insider Activity


Individual




John M. Capek



Dr. John M. Capek is Executive Vice President-Ventures at Abbott Laboratories and President at Abbott Cardiovascular Systems, Inc.
Dr. Capek was previously employed as Senior Vice President by Abbott Vascular, Inc., President by Guidant Vascular Intervention, Vice President & General Manager by Bioabsorbable Vascular Solutions, a Manager-New Product Technology by Eli Lilly & Co., Vice President & General Manager by Guidant GmbH, and Vice President-Marketing by Guidant Cardiac Rhythm Management Group.
He received his undergraduate degree from Rensselaer Polytechnic Institute, a graduate degree from Rensselaer Polytechnic Institute, an MBA from Rensselaer Polytechnic Institute, and a doctorate degree from Rensselaer Polytechnic Institute.



Transactions


Date
Shares
Transaction
Value





02/28/2017
10,815


 
Derivative/Non-derivative trans. at $45.46 per share.


491,650


02/21/2017
93,400


 
Disposition at $45 per share.


4,203,000


02/21/2017
93,400


 
Derivative/Non-derivative trans. at $26.7 per share.


2,493,780


02/17/2017
14,273


 
Award at $0 per share.


0


11/16/2016
22,000


 
Derivative/Non-derivative trans. at $24.38 per share.


536,360


02/29/2016
9,980


 
Derivative/Non-derivative trans. at $39.52 per share.


394,410


02/19/2016
24,414


 
Award at $0 per share.


0


02/27/2015
12,312


 
Derivative/Non-derivative trans. at $47.61 per share.


586,175


02/20/2015
23,457


 
Award at $0 per share.


0


02/04/2015
400


 
Disposition at $45.86 per share.


18,344


02/04/2015
300


 
Disposition at $45.75 per share.


13,725


02/04/2015
1,300


 
Disposition at $45.61 per share.


59,293


02/04/2015
2,200


 
Disposition at $45.85 per share.


100,870


02/04/2015
2,900


 
Disposition at $45.74 per share.


132,646


02/04/2015
400


 
Disposition at $45.61 per share.


18,244


02/04/2015
300


 
Disposition at $45.85 per share.


13,755


02/04/2015
700


 
Disposition at $45.74 per share.


32,018


02/04/2015
2,300


 
Disposition at $45.6 per share.


104,880


02/04/2015
100


 
Disposition at $45.84 per share.


4,584


02/04/2015
5,000


 
Disposition at $45.73 per share.


228,650


02/04/2015
200


 
Disposition at $45.6 per share.


9,120


02/04/2015
200


 
Disposition at $45.84 per share.


9,168


02/04/2015
100


 
Disposition at $45.73 per share.


4,573


02/04/2015
1,600


 
Disposition at $45.59 per share.


72,944


02/04/2015
1,935


 
Disposition at $45.83 per share.


88,682


02/04/2015
1,300


 
Disposition at $45.73 per share.


59,449


02/04/2015
1,400


 
Disposition at $45.58 per share.


63,812


02/04/2015
100


 
Disposition at $45.82 per share.


4,582


02/04/2015
2,500


 
Disposition at $45.71 per share.


114,275


02/04/2015
100


 
Disposition at $45.83 per share.


4,583


02/04/2015
2,300


 
Disposition at $45.72 per share.


105,156


02/04/2015
100


 
Disposition at $45.58 per share.


4,558


02/04/2015
500


 
Disposition at $45.82 per share.


22,910


02/04/2015
600


 
Disposition at $45.71 per share.


27,426


02/04/2015
4,300


 
Disposition at $45.81 per share.


196,983


02/04/2015
2,500


 
Disposition at $45.7 per share.


114,250


02/04/2015
400


 
Disposition at $45.81 per share.


18,324


02/04/2015
100


 
Disposition at $45.7 per share.


4,570


02/04/2015
900


 
Disposition at $45.81 per share.


41,229


02/04/2015
2,600


 
Disposition at $45.69 per share.


118,794


02/04/2015
1,373


 
Disposition at $45.8 per share.


62,884


02/04/2015
100


 
Disposition at $45.69 per share.


4,569


02/04/2015
100


 
Disposition at $45.8 per share.


4,580


02/04/2015
600


 
Disposition at $45.69 per share.


27,414


02/04/2015
1,800


 
Disposition at $45.8 per share.


82,440


02/04/2015
2,700


 
Disposition at $45.68 per share.


123,336


02/04/2015
400


 
Disposition at $45.79 per share.


18,316


02/04/2015
100


 
Disposition at $45.68 per share.


4,568


02/04/2015
200


 
Disposition at $45.79 per share.


9,158


02/04/2015
900


 
Disposition at $45.68 per share.


41,112


02/04/2015
1,100


 
Disposition at $45.79 per share.


50,369


02/04/2015
2,500


 
Disposition at $45.67 per share.


114,175


02/04/2015
800


 
Disposition at $45.83 per share.


36,664


02/04/2015
100


 
Disposition at $45.72 per share.


4,572


02/04/2015
100


 
Disposition at $45.57 per share.


4,557


02/04/2015
1,600


 
Disposition at $45.78 per share.


73,248


02/04/2015
700


 
Disposition at $45.67 per share.


31,969


02/04/2015
100


 
Disposition at $45.78 per share.


4,578


02/04/2015
3,987


 
Disposition at $45.66 per share.


182,047


02/04/2015
2,400


 
Disposition at $45.78 per share.


109,872


02/04/2015
100


 
Disposition at $45.66 per share.


4,566


02/04/2015
4,000


 
Disposition at $45.77 per share.


183,080


02/04/2015
500


 
Disposition at $45.66 per share.


22,830


02/04/2015
100


 
Disposition at $45.77 per share.


4,577


02/04/2015
2,700


 
Disposition at $45.65 per share.


123,255


02/04/2015
3,016


 
Disposition at $45.77 per share.


138,043


02/04/2015
200


 
Disposition at $45.65 per share.


9,130


02/04/2015
1,384


 
Disposition at $45.76 per share.


63,332


02/04/2015
1,700


 
Disposition at $45.64 per share.


77,588


02/04/2015
200


 
Disposition at $45.76 per share.


9,152


02/04/2015
700


 
Disposition at $45.63 per share.


31,941


02/04/2015
400


 
Disposition at $45.76 per share.


18,304


02/04/2015
300


 
Disposition at $45.63 per share.


13,689


02/04/2015
900


 
Disposition at $45.75 per share.


41,175


02/04/2015
805


 
Disposition at $45.62 per share.


36,725


02/04/2015
3,900


 
Disposition at $45.82 per share.


178,698


02/04/2015
800


 
Disposition at $45.72 per share.


36,576


02/04/2015
83,000


 
Derivative/Non-derivative trans. at $25.25 per share.


2,095,750


02/28/2014
13,263


 
Derivative/Non-derivative trans. at $39.79 per share.


527,735


02/21/2014
23,109


 
Award at $0 per share.


0


02/28/2013
15,105


 
Derivative/Non-derivative trans. at $34.26 per share.


517,498


02/19/2013
12,147


 
Derivative/Non-derivative trans. at $35.08 per share.


426,117


02/15/2013
28,800


 
Award at $0 per share.


0





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. Miles D. White 
Chairman & Chief Executive Officer




Mr. Brian B. Yoor 
Chief Financial Officer & Executive VP-Finance




Dr. Eric S. Fain 
Senior Vice President




Mr. Denis M. Gestin 
Senior VP-Global Commercial Integration




Mr. Randel W. Woodgrift 
Vice President-Global Operations




Mr. James E. Young 
Chief Compliance & Ethics Officer, Vice President




Mr. Jean-Yves F.  Pavée 
Senior Vice President-Established Pharmaceuticals




Dr. John M. Capek 
Executive Vice President-Ventures




Mr. Richard W. Ashley 
Executive Vice President-Corporate Development




Mr. Corlis D. Murray 
Senior VP-Quality Assurance & Regulatory




Mr. Brian J. Blaser 
Executive Vice President-Diagnostics Products




Dr. Gene  Huang 
Chief Economist & Vice President




Mr. John G. Stratton 
Director




Mr. Daniel J. Starks 
Director




Ms. Karen M. Peterson 
Treasurer & Vice President




Ms. Elaine R. Leavenworth 
Chief Marketing Officer & Senior Vice President




Mr. Robert E. Funck 
Vice President-Controller




Mr. Aj J. Shoultz 
Vice President-Taxes




Mr. David P. Mark 
Vice President-Internal Audit




Mr. Scott  Stoffel 
Media Relations Contact




Mr. P. Claude Burcky 
Vice President-International Government Affairs




Mr. Scott  Leinenweber 
Vice President-Investor Relations




Mr. Stephen R. Fussell 
Executive Vice President-Human Resources




Mr. Hubert L. Allen 
Secretary, Executive VP & General Counsel




Ms. Kathryn S. Collins 
Vice President-Commercial Legal Operations




Mr. Samuel C. Scott 
Independent Director




Mr. Glenn Fletcher Tilton 
Independent Director




Mr. Edward Michael Liddy 
Independent Director




Ms. Phebe N. Novakovic 
Independent Director




Dr. Robert J. Alpern 
Independent Director




Mr. William A. Osborn 
Lead Independent Director




Mr. Jim  Farrell 
Independent Director




Ms. Roxanne Schuh Austin 
Independent Director




Dr. Sally E. Blount 
Independent Director




Ms. Nancy  McKinstry 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




3:22 PM EDT
July 24, 2017


/marketstate/country/us
New York

	Open


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
3:18pTrump administration stymies push for improved climate-risk disclosure among companies
3:17pAlphabet earnings: A $2.74 billion hit for Google, potential YouTube results for investors
3:17pBoeing earnings: Management will likely make a big deal about its services business
3:07pNo retreat: Fed to stick to plans for rate hike, balance-sheet selloff this year
3:06pConstellation Brands, Boston Beer shares slide after Goldman Sachs downgrades
3:06pAMD puts Intel in the crosshairs with fast-and-cheap Threadripper chip
3:03pWhy you should be worried about this part of the New York real-estate market
3:03pBarron's Bounce: Meaty Gains for Leucadia
3:01pGold settles lower, ending 6-session streak of gains
3:01pHow housekeepers, takeout food and grocery delivery are making us happier
2:58pDow, S&P 500 edge lower while Nasdaq sets intraday record 
2:56pBoston Beer downgraded to sell at Goldman Sachs
2:56pCPRRECTED" Constellation Brands downgraded to neutral at Goldman Sachs
2:55pCORRECTED: Goldman Sachs sets Constellation Brands price target at $210
2:50p‘Game of Thrones’ science: Let’s take a closer look at that greyscale
2:49pOil prices finish higher after news of Saudi pledge to cut exports, Nigeria plans to cap output
2:49pConstellation Brands shares down 1.2% 
2:47pMove over, Airbnb: Here’s how to rent out your home for a lot more money
2:47p‘Robot parents’ can even read your child bedtime stories
2:46pCompanies do better when CEO pay dwarfs average worker, study finds
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,541.74

-38.33
-0.18%





nasdaq

/quotes/zigman/12633936/realtime
6,411.88

+24.13
+0.38%





s&p 500

/quotes/zigman/3870025/realtime
2,472.09

-0.45
-0.02%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15

























































John M Capek - Midlothian, IL | Intelius



























Sign In



We found John M Capek in Midlothian, IL


John M Capek

                                                                           Intelius found that John M Capek  is  a male between 60 and 60 years old from Midlothian, IL.  We have connected them to
                12 addresses,
                7 phones,
                and 8 relatives or associates.
         






Get Report Now

Age

John M Capek is in his 60s

John Has Lived In

Midlothian, IL
Palos Park, IL
Frankfort, IL

John's Relatives

Matthew Capek
James Capek
Kim Capek
Janet Capek







John M Capek



Zodiac SignSagittarius



GenderMale



Get Report Now










Want to know more about John? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about John, or use our people search engine to find others.
Get Background Check on John M Capek
Get a Criminal Check on John M Capek
Get a Public Record Report on John M Capek
Get a People Search Report on John M Capek


John M Capek's Contact Information
Known Cities Lived In
Find out where John M Capek has lived as well as John M Capek's phone numbers and email addresses.




John M Capek Has Lived in 2 States
Illinois Address for John M Capek


5130 1**** S* 

Midlothian, IL


Has Lived In

Midlothian, IL
Palos Park, IL


Get Full Address Report










Phone Numbers Associated with John M Capek

(708) ***-**** - Midlothian, IL 
(312) ***-**** - Palos Heights, IL 
() ***-**** - Palos Heights, IL 


Get Full Phone Report



Email Addresses Associated with John M Capek

j*******k@***.com
j****k@***.com
m*****k@***.com


Get Email Report




John M Capek's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for John M Capek


John M Capek's known Social Networks And Potential Email Matches

Find all of John M Capek's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
John Capek
Username Matches

                  JohnCapek
                  CapekJohn
                  John.Capek
                  Capek.John
                  John_Capek
                  Capek_John
                  John-Capek
                  Capek-John
                  JCapek
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
J Capek







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.











